Biotech Giant AnaptysBio Plans Spin-Off Amid Strong Revenue Growth in 2026 | MarketWire

AnaptysBio shares climbed after signaling a spin-off and robust sales momentum. Investors weigh potential growth opportunities in the biotech sector.

Read full article on MarketWire